Cynanchum bungei Decne-derived extracellular vesicles alleviate cognitive impairment and pathological damage in Alzheimer’s disease
Open Access
- 10 April 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 20, 1798965
Abstract
Introduction: Cynanchum bungei Decne (CB) is known for its therapeutic benefits for neurodegenerative conditions as anti-inflammatory, antioxidant, and barrier significantly limits their potential advantages. Given the ability of crossing the barrier with minimal toxicity, extracellular vesicles derived from CB (CB-EVs) were utilized as an innovative approach to mitigate Alzheimer’s disease (AD). Methods: CB-EVs were isolated using gradient ultracentrifugation and identified via TEM imaging, nanoparticle tracking analysis, marker identification, and in vivo imaging system. Ten-month-old triple transgenic AD (3xTg-AD) mice received intravenous administration of CB-EVs at doses of 10 or 20 mg/kg every 3 days for the cognitive and pathological assessments. The human APP Swedish mutation transgenic SH-SY5Y cells were constructed as Aβ-induced neural damage model, and different concentrations of CB-EVs were added into medium to analyze its roles on cell viability, transcriptome changes, oxidative stress, and mitochondrial damage. Results: CB-EVs exhibited standard morphological and molecular traits, accumulating in the cerebral cortex and hippocampus. Two months of CB-EVs treatment alleviated cognitive impairments, diminished Aβ plaque, reduced Tau protein hyperphosphorylation, and lessened neuronal loss in 3xTg-AD mice. In transgenic SH-SY5Y cells, CB-EVs improved cell viability, enhanced superoxide dismutase activity, downregulated oxidative stress related NUPR1 and CHOP expression, decreased reactive oxygen species, lipid peroxidation, and malondialdehyde levels, reduced mitochondrial damage. Conclusion: These results demonstrated that CB-EVs could protect neurons from oxidative stress, attenuate cognitive impairment and pathological damage in AD.Keywords
This publication has 38 references indexed in Scilit:
- Integration of phytochemical profiling and computational approaches to evaluate the neuroprotective potential of Nardostachys jatamansi in Alzheimer's diseaseBiotechnology Reports, 2025
- Innovative approaches to Alzheimer's therapy: Harnessing the power of heterocycles, oxidative stress management, and nanomaterial drug delivery systemAgeing Research Reviews, 2024
- Lepidium meyenii Walp (Maca)‐derived extracellular vesicles ameliorate depression by promoting 5‐HT synthesis via the modulation of gut–brain axisiMeta, 2023
- Alzheimer’s disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugsBiochemical Pharmacology, 2023
- Dual functional antioxidant and butyrylcholinesterase inhibitors for the treatment of Alzheimer’s disease: Design, synthesis and evaluation of novel melatonin-alkylbenzylamine hybridsBioorganic & Medicinal Chemistry, 2022
- Plant‐derived extracellular vesicles: Recent advancements and current challenges on their use for biomedical applicationsJournal of Extracellular Vesicles, 2022
- Astrocyte calcium dysfunction causes early network hyperactivity in Alzheimer’s diseaseCell Reports, 2022
- Mitochondrial dysfunction, oxidative stress, neuroinflammation, and metabolic alterations in the progression of Alzheimer’s disease: A meta-analysis of in vivo magnetic resonance spectroscopy studiesAgeing Research Reviews, 2021
- Cynanchum bungei Decne and its two related species for “Baishouwu”: A review on traditional uses, phytochemistry, and pharmacological activitiesJournal of Ethnopharmacology, 2019
- In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid β-peptide of APPFree Radical Biology and Medicine, 2010